Combination Chemotherapy With TS-1 and Cisplatin for Urinary Adenocarcinoma: A Retrospective Case Series

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-07-03 DOI:10.1016/j.clgc.2024.102149

Akifumi Omiya , Satoshi Nitta , Shuya Kandori , Reo Takahashi , Ichiro Chihara , Masanobu Shiga , Kosuke Kojo , Yoshiyuki Nagumo , Atsushi Ikeda , Takashi Kawahara , Akio Hoshi , Bryan J. Mathis , Hiromitsu Negoro , Hiroyuki Nishiyama

{"title":"Combination Chemotherapy With TS-1 and Cisplatin for Urinary Adenocarcinoma: A Retrospective Case Series","authors":"Akifumi Omiya , Satoshi Nitta , Shuya Kandori , Reo Takahashi , Ichiro Chihara , Masanobu Shiga , Kosuke Kojo , Yoshiyuki Nagumo , Atsushi Ikeda , Takashi Kawahara , Akio Hoshi , Bryan J. Mathis , Hiromitsu Negoro , Hiroyuki Nishiyama","doi":"10.1016/j.clgc.2024.102149","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>Urinary adenocarcinoma is a rare histological subtype in urinary tract cancers and standard chemotherapy regimens remain unestablished. We retrospectively analyzed the clinical information of patients with rare urinary adenocarcinoma who received TS-1 plus cisplatin chemotherapy at the University of Tsukuba Hospital. In this study, a total of 9 patients were included and 1 and 3 had complete or partial responses, resulting in an overall response rate of 44%. The median follow-up period was 21.2 months (range, 8.5-91.6). The median OS and PFS were 16.2 months (range, 3.6-90.2) and 4.8 months (range, 1.7-20.0), respectively. The major adverse events over Grade 3 were neutropenia in 2 patients (22%) and anemia in 1 patient (11%). This study suggests the efficacy and safety of TS-1 in combination with cisplatin with regard to rare urinary adenocarcinoma. Multicenter, large, and prospective studies are necessary to validate these findings.</p></span></li></ul></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324001204","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

•
Urinary adenocarcinoma is a rare histological subtype in urinary tract cancers and standard chemotherapy regimens remain unestablished. We retrospectively analyzed the clinical information of patients with rare urinary adenocarcinoma who received TS-1 plus cisplatin chemotherapy at the University of Tsukuba Hospital. In this study, a total of 9 patients were included and 1 and 3 had complete or partial responses, resulting in an overall response rate of 44%. The median follow-up period was 21.2 months (range, 8.5-91.6). The median OS and PFS were 16.2 months (range, 3.6-90.2) and 4.8 months (range, 1.7-20.0), respectively. The major adverse events over Grade 3 were neutropenia in 2 patients (22%) and anemia in 1 patient (11%). This study suggests the efficacy and safety of TS-1 in combination with cisplatin with regard to rare urinary adenocarcinoma. Multicenter, large, and prospective studies are necessary to validate these findings.

查看原文本刊更多论文

采用 TS-1 和顺铂联合化疗治疗泌尿系统腺癌：回顾性病例系列研究

-泌尿系统腺癌是泌尿系统癌症中一种罕见的组织学亚型，标准化疗方案仍未确定。我们回顾性分析了在筑波大学医院接受 TS-1 加顺铂化疗的罕见泌尿系统腺癌患者的临床信息。本研究共纳入 9 例患者，其中 1 例和 3 例患者有完全或部分反应，总反应率为 44%。中位随访期为 21.2 个月（8.5-91.6 个月）。中位OS和PFS分别为16.2个月（范围为3.6-90.2）和4.8个月（范围为1.7-20.0）。3级以上的主要不良反应为2名患者（22%）出现中性粒细胞减少，1名患者（11%）出现贫血。这项研究表明，TS-1 联合顺铂治疗罕见泌尿系统腺癌具有疗效和安全性。有必要进行多中心、大规模和前瞻性研究来验证这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464